Instructions for Noojerone (memantine)
English Product Name
Noojerone
Release Form
Coated tablets
Description Noojerone
Gray-coated tablets are oval, biconvex, engraved "10" and risked between the numbers on one side and the "MM" engraving and the risk between the letters on the other side; cross-sectioned, white or nearly white core.
1 tab
memantine hydrochloride 10 mg,
which corresponds to the content of the memantine 8.31 mg
Auxiliary substances: microcrystalline cellulose - 136.8 mg, calcium hydrophosphate - 84.5 mg, crosscarmellose sodium - 4.8 mg, silicon colloidal - 1.5 mg, magnesium stearate - 2.4 mg.
The composition of the film shell: opadrai II gray 45F27505 - 8 mg (hypromellose 2910/15sR - 2.5 mg, polydextrose - 2.5 mg, titanium dioxide - 2.48 mg, macrogol/macrogol 4000 - 0.5 mg, iron oxide black dye - 0.02 mg).
ATX codes
N06DX01 Memantine
Clinical and pharmacological groups / Group affiliation
NMDA glutamate receptor blocker. Drug to treat dementia
Active ingredient Noojerone
memantine hydrochloride
Pharmacotherapeutic group
Dementia medication
Retention conditions Noojerone
The drug should be stored in a place inaccessible to children at a temperature not exceeding 25 °C.
Expiration date
Shelf life - 3 years
Pharmacological effect Noojerone
The mechanism of action of this drug is based on the derivative of adamantane, which is a non-competitive antagonist of NMDA receptors, acting on the glutamatergic system. It regulates ion transport, blocks calcium channels, normalizes membrane potential, and improves nerve conduction. This drug contributes to improving cognitive processes and increasing daily activity.
Testimony Noojerone
use includes moderate to severe Alzheimer dementia.
Application, treatment and dosage Noojerone
The procedure is performed under the supervision of a doctor who has experience in the diagnosis and treatment of dementia in Alzheimer's disease. Treatment should be started only if the caregiver controls the drug. Diagnosis should be made according to existing guidelines.
Tolerance and dosage of noodgeron should be assessed regularly, mainly within three months of initiation of therapy. Clinical efficacy and tolerability should then be regularly assessed according to current clinical guidelines. The maintenance treatment can be continued for a long time while maintaining therapeutic efficacy and good tolerability of the drug noodgeron. The drug should be stopped if there is no therapeutic effect or if the patient does not tolerate the treatment.
Noodgeron is taken by mouth once a day. The drug should be taken at the same time every day regardless of food intake.
A gradual increase of 5 mg/week during the first three weeks of therapy is recommended to reduce the risk of side effects.
The maximum daily dose is 20 mg.
The recommended maintenance dose of noodgeron is 20 mg per day.
Recommended dosing regimen:
1st week (day 1 to 7): 5 mg/day (1/2 tablet)
Week 2 (8 to 14 days): 10 mg/day (1 tablet)
3rd week (15 to 21 days): 15 mg/day (1 and 1/2 tablet)
Beginning in the 4th week: 20 mg/day (2 tablets).
For patients over age 65, no dose adjustment is needed.
In patients with a renal glomerular filtration score of 50 to 80 mL/min, no dose adjustment is required. For moderate renal failure (estimated glomerular filtration score 30 to 49 mL/min), the recommended dose is 10 mg/day; if the drug is tolerated, the dose can be increased up to 20 mg/day for 7 days as standard. In patients with severe renal insufficiency (glomerular filtration assessment 5 to 29 mL/min), the daily dose should not exceed 10 mg.
For patients with mild to moderate liver dysfunction (Child-Pugh class A and B), no dose adjustment is necessary. Noodgeron is contraindicated in patients with severe liver failure (Child-Pugh class C).
